Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | ERN1 | O75460 | 8/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | F3 | P13726 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275397 | 0.84 | ERN1 (0.57) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL4357334 | 0.80 | TDP1 (0.70) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL29889164 | 0.78 | TDP1 (1.00) | TDP1ERN1HSD17B10ALDH1A1 | |
| SCHEMBL95435 | 0.78 | TDP1 (1.00) | TDP1ERN1HSD17B10ALDH1A1 | |
| SCHEMBL95555 | 0.78 | ERN1 (0.56) | TDP1ERN1MEN1LMNATHRB | |
| Water SCHEMBL28578537 | 0.78 | TDP1 (0.67) | TDP1ERN1HSD17B10MEN1LMNA | |
| Ammonia Solution, Strong SCHEMBL8037724 | 0.76 | TDP1 (0.95) | TDP1ERN1HSD17B10ALDH1A1 | |
| SCHEMBL27651048 | 0.76 | TDP1 (0.57) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL24014740 | 0.74 | ERN1 (0.42) | TDP1ERN1MEN1LMNATHRB | |
| SCHEMBL155661 | 0.74 | TDP1 (0.61) | TDP1ERN1HSD17B10LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| US-9926275-B2 | Allosteric modulators of the cannabinoid 1 receptor | NORTHEASTERN UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| WO-2011033115-A2 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-24 | — | — | WO | disclosed |
| CN-101896486-A | Spiroindolinone derivatives | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | PTGDR2, PTGDR, PTGER2 | TDP1 4856/4885ERN1 3380/4885HSD17B10 1483/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | TDP1 1661/4885ERN1 3123/4885HSD17B10 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.